Corvus Pharmaceuticals is taking a multi-pronged approach to treat patients with the most difficult-to-treat diseases. There is much therapeutic need for treating the most advanced stages of diseases in cancer, immune disorders and infectious diseases. Corvus is using a clinical science-driven approach to pioneer precisely targeted medicines for these diseases. Corvus has five proprietary agents in the pipeline, comprising both small molecules and antibodies, with differentiated mechanisms of action, some of which are in Phase 1 clinical trials. This includes CPI-818, an oral, small molecule that inhibits an enzyme expressed predominantly in T cells to treat T cell lymphomas.

Corvus Pharmaceuticals

Founded: 2014
Location: Burlingame, CA
Employee range: 50 - 200
Clinical stage: Clin2
Therapy area: Renal cell carcinoma
Drug types: ONC, DRM, IMM, ALL
Lead product: Ciforadenant
Funding: $10M stock May 2021; $34.2M stock Feb 2021

Drug notes:

About:

Jobs: